Avicanna Inc. announced it has entered into a research collaboration with a multi-national European-based pharmaceutical company (?Collaborator?). The research collaboration will initially assess the Company?s proprietary SEDDS technology in combination with Collaborator?s various drug delivery and pharmaceutical formats to gain a better understanding of proprietary dosage forms with precisely standardized delivery and enhanced bioavailability of cannabinoids. The research collaboration may subsequently assess the possibility of further preclinical research and clinical development.

Under the research collaboration, Avicanna will also provide services for assessing a range of other formulations that may be included in Collaborator?s portfolio.